Le Lézard
Classified in: Health
Subjects: PDT, REL

InventHelp Inventor Develops Device to Defeat The Devil (CHK-905)


PITTSBURGH, Aug. 16, 2023 /PRNewswire/ -- "I wanted to create a device for the deadly serious purpose of literally defeating the devil in your mind, heart and life," said an inventor, from Naperville, Ill., "so I invented the DEFEAT THE DEVIL. My design is meant to scare and stop listeners from sinning by instilling the fear of the Lord and Hell's unquenchable fire."

The invention provides an inspirational and educational device that would help Christians and others make the right choices and defeat the devil inside them. In doing so, it can be used to scare listeners and prevent them from doing the work of the devil. It also would educate users with Scriptures and other facts. The invention features an innovative design that is easy to use so it is ideal for Christians, would-be mass shooters, gang-bangers, pedophiles, and others tempted to sin and do the work of the devil.

The original design was submitted to the Chicago sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 21-CHK-905, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com.

SOURCE InventHelp


These press releases may also interest you

at 16:05
Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
Ironwood Pharmaceuticals, Inc. today announced that management will participate in a fireside chat at The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 10:00 a.m. ET at the New York Hilton Midtown. A live audio webcast of...

at 16:05
Vertex Reports First Quarter 2024 Financial Results
Vertex Pharmaceuticals Incorporated today reported consolidated financial results for the first quarter ended March 31, 2024, and reiterated full year 2024 financial guidance. "Vertex delivered a strong start to 2024 with 13 percent product...

at 16:05
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on May 1, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...

at 16:05
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET
Enanta Pharmaceuticals, Inc. , a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal second quarter ended March 31, 2024. "At...

at 16:05
FDA Approves ColoSensetm ? Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test
Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of gastrointestinal health, today announced that the U.S. Food and Drug Administration (FDA) approved its noninvasive colorectal cancer screening...

at 16:05
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the grant of inducement awards to seven new employees. The Compensation...

More news about Health...


News published on and distributed by: